What is pemigatinib, and what is it used for?
Pemigatinib (Pemazyre) is a targeted cancer medicine that inhibits FGFR (fibroblast growth factor receptor) signaling. It is used to treat certain cancers with FGFR gene changes, including cholangiocarcinoma (bile duct cancer) with FGFR2 fusions or rearrangements, and other FGFR-altered solid tumors depending on the approved indication and the patient’s specific genetic alteration [1].
How does pemigatinib work?
Pemigatinib blocks FGFR activity. When cancers have FGFR alterations (such as gene fusions/rearrangements), FGFR signaling can drive tumor growth. By inhibiting FGFR, pemigatinib aims to slow or stop cancer progression in tumors that depend on that pathway [1].
Who should be tested before using pemigatinib?
People considered for pemigatinib need molecular testing to confirm an FGFR alteration that matches the drug’s indication. The key practical point is that treatment is tied to the presence of specific FGFR gene changes, not just the cancer type alone [1].
How is pemigatinib taken?
Pemigatinib is taken as an oral medication (tablets), using an established schedule and dose for the approved indication. Clinicians typically adjust dosing based on tolerability and lab monitoring results, especially for known class effects like phosphate changes and eye/visual symptoms [1].
What side effects do people ask about?
Commonly reported and clinically monitored effects for pemigatinib include changes in blood phosphate levels and other tolerability issues. Patients are also advised to watch for vision-related symptoms and to follow prescriber instructions for lab work and symptom reporting during treatment [1].
What monitoring is required during treatment?
Because pemigatinib affects FGFR signaling and can cause metabolic and ocular effects, treatment generally involves periodic lab monitoring (including phosphate) and ongoing clinical monitoring for adverse effects. Monitoring plans depend on the individual and the specific protocol used by the treating oncology team [1].
How is pemigatinib different from other FGFR inhibitors?
Pemigatinib is one option among FGFR-targeted therapies. Differences between agents typically involve which FGFR alterations are addressed, how the drug is dosed, and the specific safety profile and monitoring requirements. Choosing among FGFR inhibitors is usually guided by the tumor’s genetic alteration, prior therapies, and the approved labeling for each drug [1].
Where to find regulatory/label details
If you’re looking for the exact approved indications, dosing schedules, and monitoring language, the prescribing information for Pemazyre is the authoritative source, including eligibility criteria based on FGFR alterations [1].
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/ (FDA drug label database; search for “Pemazyre pemigatinib prescribing information”)